Constance Guille, M.D., a reproductive psychiatrist and the director of the MUSC Women’s Reproductive Behavioral Health Program, details the first FDA-approved treatment for moderate to severe postpartum depression. This treatment, a brexanolone (Zulresso) infusion, provides symptom relief within days instead of the weeks or months required with traditional antidepressants. Guille also discusses the far-reaching impacts of mood and anxiety disorders on pregnant and postpartum women as well as their children.